Original Article Open Access
Copyright ©2012 Baishideng. All rights reserved.
World J Stem Cells. Jun 26, 2012; 4(6): 53-61
Published online Jun 26, 2012. doi: 10.4252/wjsc.v4.i6.53
Isolation and characterisation of mesenchymal stem cells derived from human placenta tissue
Shalini Vellasamy, Pratheep Sandrasaigaran, Sharmili Vidyadaran, Rajesh Ramasamy, Immunology Laboratory, Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia
Elizabeth George, Haematology Unit, Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia
Author contributions: All authors contributed to this study.
Supported by Research University Grant Scheme, Universiti Putra Malaysia, No. 04-01-09-0781RU; and Science Fund, Ministry of Science, Technology and Innovation, Malaysia, No. 02-01-04-SF1022
Correspondence to: Rajesh Ramasamy, PhD, Immunology Unit, Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia. r.rajesh@medic.upm.edu.my
Telephone: +60-3-89472377 Fax: +60-3-89412787
Received: August 22, 2011
Revised: March 6, 2012
Accepted: March 15, 2012
Published online: June 26, 2012


AIM: To explore the feasibility of placenta tissue as a reliable and efficient source for generating mesenchymal stem cells (MSC).

METHODS: MSC were generated from human placenta tissue by enzymatic digestion and mechanical dissociation. The placenta MSC (PLC-MSC) were characterized for expression of cell surface markers, embryonic stem cell (ECS) gene expression and their differentiation ability into adipocytes and osteocytes. The immunosuppressive properties of PLC-MSC on resting and phytohemagglutinin (PHA) stimulated allogenic T cells were assessed by means of cell proliferation via incorporation of tritium thymidine (3H-TdR).

RESULTS: The generated PLC-MSC appeared as spindle-shaped cells, expressed common MSC surface markers and ESC transcriptional factors. They also differentiated into adipogenic and osteogenic lineages when induced. However, continuous cultivation up to passage 15 caused changes in morphological appearance and cellular senescence, although the stem cell nature of their protein expression was unchanged. In terms of their immunosuppressive properties, PLC-MSC were unable to stimulate resting T cell proliferation; they inhibited the PHA stimulated T cells in a dose dependent manner through cell to cell contact. In our study, MSC generated from human placenta exhibited similar mesenchymal cell surface markers; MSC-like gene expression pattern and MSC-like differentiation potential were comparable to other sources of MSC.

CONCLUSION: We suggest that placenta tissues can serve as an alternative source of MSC for future experimental and clinical studies.

Key Words: Mesenchymal Stem Cell, Placenta, Immunophenotyping, Immunomodulation, Growth Kinetics


A substantial amount of research over the past two decades has resulted in greater understanding of human adult stem cell biology not only in the basic sciences but also in relation to therapeutic usage[1,2]. Among stem cells, mesenchymal stem cells (MSC) have become an important component in stem cell-based neo-therapies for tissue regeneration and transplantation. MSC are widely distributed in a variety of adult tissues such as adipose tissue, bone, lung, peripheral blood and are either constantly present or their pool is replenished due to migration from the bone marrow[3-5]. It was recently demonstrated that MSC are also present in umbilical cord blood, placenta and foetal tissues[4,6].

Unlike other stem cells, MSC derived from bone marrow have been investigated extensively for their immunosuppressive activity and have been exploited in treating autoimmune diseases as well as graft vs host disease (GVHD)[7]. Current literature indicates MSC-exerted immunosuppression is an important modulator in the allogenic immune response that involves mainly lymphocytes[8-10] and antigen presenting cells[11,12]. Some of these effects have been well exploited in therapeutics, such as in induction of tolerogenic response in GVHD[7,13] and enhanced antitumor therapy[14,15]. In addition, studies in animal models have shown that transplanted MSC have the potential to migrate to sites of injury, differentiate into appropriate phenotype and regenerate the injured tissue[16-20].

Bone marrow is the are the most extensively studied source of MSC (BM-MSC). However, BM-MSC have to be aspirated using an invasive procedure that can cause discomfort to the donor. This limited accessibility is couple with relatively low cell yield (0.001%-0.01%), with the numbers of stem cells significantly decreasing with age[21,22]. MSC derived from embryonic and aborted foetal tissues can overcome the volumetric problem but their usage in clinical application and research is still hindered by ethical issues and remains controversial. To overcome these problems, an alternative source of MSC which avoids ethical issues and is easily accessible at low cost is recommended.

In this study, we assessed the presence of MSC in human delivery waste tissues such as placenta which are more readily available for research at low cost[23]. We have showed that the MSC generated from human placenta tissues were able to expand and express similar characteristics as of BM-MSC in terms of mesenchymal and functional properties. We have also documented that placental MSC undergo cellular senescence as detected by morphological changes and thereby impose limitations on the culture expansion.

Generation of MSC from human placenta tissue

Placenta samples (n = 5) were collected upon delivery from normal full term pregnancies with the assistance of gynaecologists from Britannia Women and Children Specialist Centre. All samples were obtained with written, informed consent in accordance with the ethical committee requirements of the Faculty of Medicine and Health Sciences, Universiti Putra Malaysia. The human placenta tissues were processed using our established mechanical disassociation and enzymatic digestion method[15]. Briefly, placenta tissue was minced into a paste-like consistency and digested in enzymatic mixtures containing 0.4% type II collagenase (Worthington, New Jersey, USA) and 0.01% DNAse (Worthington, New Jersey, USA). Following this, tissues were mechanically dissociated using a hand held cell homogenizer (Hassen Wagger). The single cell suspension was resuspended in MSC complete media containing Dulbecco’s Modified Eagle’s medium with nutrient mixtures F-12 (HAM) (1:1) with GLUTAMAX-I (Gibco, Invitrogen, USA), 10% foetal bovine serum (Stem Cell Technology Inc., London, UK), 1% Penicillin and Streptomycin (Gibco, Invitrogen), 0.5% Fungizone (Gibco, Invitrogen), 0.1% Gentamicin (Gibco, Invitrogen) and 40 ng/mL basic fibroblastic growth factor (bFGF) (Promega). The single nucleated cells (30 × 106 cells/T25 culture flask) were cultured in MSC complete media. Primary cultures were incubated for at least a week in a 37 °C humidified 5% CO2 incubator and non-adherent cells were removed by replacing the media. Upon reaching 70% to 80% confluence, adherent MSC were harvested via trypsinisation (0.05% trypsin-EDTA, Invitrogen, BRL, Canada) for use in downstream experiments.

Immunophenotyping of PLC-MSC

Placenta MSC (PLC-MSC) were stained with a panel of MSC specific monoclonal antibodies: CD73-PE, CD29-PE, CD90-PE, MHC I-PE-Cy5, MHC II-FITC, CD45-FITC, CD34-FITC, CD80-PE, CD86-APC, (Becton Dickinson, Biosciences Pharmingen) and CD105-FITC, STRO-1-FITC (RandD System). 7-amino-actinomycin-D (7-AAD) (BD Pharmingen) was added for dead cell discrimination. Immunophenotyping was performed on the same cells aliquoted equally into different tubes according to experimental design. Stained cells were re-suspended in PBS, analysed using FACSCalibur flow cytometer (Becton Dickinson). The computed data were analysed using CellQuestPro software provided by the manufacturer.


Total RNA was extracted from PLC-MSC, differentiated adipocytes and osteocytes using TRIzol® Reagent (Invitrogen, USA). RT-PCR was performed using the ImPromII™ Reverse Transcription System (Promega, USA) and cDNA and Taq DNA Polymerase kit (Qiagen). Genes of interest were obtained using primers synthesized from EUROGENTEC AIT as shown in Table 1.

Table 1 Primers for transcription factors for indicated genes.
GeneForward primerReverse primer
Differentiation assay

PLC-MSC at 100% confluence were induced to differentiate into adipocytes, and osteocytes using MSC Adipogenesis Kit and MSC Osteogenesis Kit (CHEMICON). Adipogenesis induction medium contained 10% FBS, 1 μmol/L dexamethasone, 0.5 mmol/L IBMX, 10 μg/mL insulin, 100 μmol/L indomethacin, 1% Penicillin and Streptomycin and 90% DMEM/F12. Osteogenesis induction medium consisted of 10% FBS, 0.1 μmol/L dexamethasone solution, 0.2 mmol/L ascorbic acid 2-phosphate solution, 10 mmol/L glycerol 2-phosphate, 1% Penicillin and Streptomycin and 87% DMEM/F12. After differentiation, the adipocytes and osteocytes were fixed and stained with Oil Red O Solution and Alizarin Red Solution respectively. Chondrogenesis was induced using a Chondrocyte Differentiation Kit (STEMPRO®). Micromass cultures were generated by seeding 5 μL (1.6 × 107 cells/mL) droplets and were cultured in Chondrogenesis differentiation medium contained fresh 90% STEMPRO® Chondrocyte Differentiation Basal Medium and 10% STEMPRO® Chondrogenesis Supplements. After 21 d of cultivation, the chondrocytes were fixed and stained with 1% Alcian Blue solution and visualized under light microscope.

Growth Kinetics and doubling time

PLC-MSC (4 × 103 cell/well) were plated into 6-well plates and incubated at 37 °C in a 5% CO2 humidified incubator. Media was changed twice weekly. Triplicates of PLC-MSC were harvested every 2 d until day 14 using 0.05% trypsin-EDTA and the growth curve of PLC-MSC was determined by performing trypan blue exclusion cell counts. About 0.3 × 106 of MSC from every passages were cultured in 100 mm Petri dishes and a trypan blue cell count was performed when the cells had attained full confluency. The initial seeding, days in culture and cell yield were recorded and the doubling time determined using the Patterson Formula [Td = Tlg2/lg (Nt/N0)], Td is the doubling time (h), T is the time taken for cells to proliferate from N0 to Nt (hour), and N is the cell count.

T cell proliferation assay

PLC-MSC was co-cultured with T cells at 1:5, 1:10, 1:50 and 1:100 ratios in a 96 well plate and stimulated with phytohemagglutinin (PHA) (Roche). Cultures were incubated for 72 h and pulsed with Tritium thymidine (3H-TdR) [0.037 MBq/well (0.5 μCi/well) (Perkin Elmer)] for the final 18 h of incubation. At 72 h, cells were harvested onto glass fiber filter mats A (Perkin Elmer) using a 96 well plate manual cell harvester (MACH IIIM-FM, Tomtec, Inc. Hamden, CT USA). Scintillation cocktail was added and thymidine incorporation was measured by liquid scintillation spectroscopy using the Microbeta Trilux β counter (Pelkin Elmer). For transwell assays, T cells were physically separated from PLC-MSC by transwell chambers with 1 μm pore size membrane (Becton Dickinson).

Statistical analysis

The data were expressed as mean ± SE. The Student t-test was performed to compare the values of two means. Significance level was determined as P < 0.05.

PLC-MSC exhibit mesenchymal morphological features

Formation of heterogeneous monolayer, adherent and spindle shaped fibroblast-like cells were observed for PLC-MSC and an average of 14 d was required for PLC-MSC to attain confluence (Figure 1A). The initial growth of PLC-MSC cultures at passage 0 (P0) consisted of two different heterogeneous populations; one with fibroblast-like morphology and the other with epithelial-like morphology. Upon trypsinisation and sub-cultivation, the epithelial-like population disappeared from the culture and could no longer be found in subsequent passages (Figure 1B). PLC-MSC were successfully cultured and expanded till P15. At early passages, MSC were obtained with well-defined smaller sized spindle shaped cells. However, these features gradually changed at later passages (P15 onwards). PLC-MSC at later passages appeared less defined, larger in size, less adherent and produced more debris in the culture supernatant (Figure 1C).

Figure 1
Figure 1 Morphology of placenta mesenchymal stem cells primary cultures. A: The formation of heterogeneous populations of placenta mesenchymal stem cells (PLC-MSC) with fibroblastic and epithelioid morphologies at passage 0, P0 until confluence at day 14; B: Homogenous population of PLC-MSC at P1; Disappearance of the epitheloid population and appearance of fibroblast-like cells upon trypsinisation and passaging; C: Comparison of early and late passages of primary MSC cultures (C). Photomicrographs taken using phase contrast microscope at magnification 100 ×.
Expression profile of PLC-MSC

Immunophenotyping of PLC-MSC was performed from P2 to P15. At early passage (P2), more than 90% of PLC-MSC were positive for integrin markers (CD29), mesenchymal markers (CD105 and CD73), CD90 and major histocompatibility class I antigen (MHC I) (Figure 2). All samples showed negative expression for hematopoietic cell markers (CD45 and CD34), co-stimulatory molecules (CD80 and CD86) and major histocompatibility class II antigen (MHC II). RT-PCR showed that PLC-MSC express embryonic stem cell (ESC) transcriptional factors such as Nanog, Sox2, Rex1and Oct4 (Figure 3). Expression of these markers was consistent for the subsequent passages.

Figure 2
Figure 2 Immunophenotyping of placenta mesenchymal stem cells by flow cytometry. Adherent placenta mesenchymal stem cells (MSC) were harvested upon confluence and stained for MSC cell surface markers using a panel of anti human antibodies. Results represent at least 3 experiments.
Figure 3
Figure 3 Gene expression by reverse transcription-polymerase chain reaction of placenta mesenchymal stem cells. Placenta mesenchymal stem cells express markers of embryonic stem cell transcriptional factors such as Nanog, Sox2, Rex-1 and Oct4. GAPDH was used as a reference gene. 100 bp DNA ladder was used as a marker.
PLC-MSC differentiate into mesodermal lineages

MSC were induced for adipogenic, osteogenic and chondrogenic differentiation along with standard culture medium as control. Histochemistry evaluation of PLC-MSC in inductive cultures showed their ability to differentiate into adipocytes, osteocytes and chondrocytes (Figure 4A). Adipogenic induction resulted in formation of lipid vacuoles which stained red with Oil-Red-O, whereas osteogenic induction resulted in deposition of calcium minerals (stained orangy-red with Alizarin Red). Chondrogenic induction resulted in formation of proteoglycans, stained blue by Alcian Blue solution. Images were captured using a phase contrast microscope. RNA analysis confirmed the osteogenic differentiation of PLC-MSC as the cells in osteogenic induction media expressed mRNA for the osteocalcin (OC) and osteopontin (OP) (Figure 4B).

Figure 4
Figure 4 Differentiation potential of placenta mesenchymal stem cells into mesodermal lineages. A: Placenta MSC (PLC-MSC) after 3 wk in adipogenic or osteogenic or normal cell culture medium. Formation of lipid droplets (stained red in Oil-Red-O), calcium deposition (stained orangy-red in Alizarin Red) and formation of proteoglycans (stained blue in Alcian Blue) confirms the ability to differentiate into mesodermal lineages. The picture was taken using phase contrast microscope at 100 × magnification. B: PLC-MSC differentiated into osteocytes expresses Osteocalcin (OC) and Osteopontin (OP) (data from two independent experiments). M: 100 bp DNA ladder; N: Non template control as negative control; C: Control-undifferentiated PLC-MSC; G1: GAPDH for differentiated PLC-MSC; G2: GAPDH for control.
Growth Kinetics analysis of PLC-MSC

Growth kinetics of PLC-MSC at early passage P3 (Figure 5A) showed a shorter lag-phase at day 1-6, followed by a rapid log-phase from day 6-12 until a plateau was reached. On average, the doubling time of PLC-MSC (Figure 5B) was 41 h.

Figure 5
Figure 5 Growth Kinetics of placenta mesenchymal stem cells. Placenta mesenchymal stem cells (PLC-MSC) (4000 cells/well) were plated in 6 well plates and medium was changed three times a week. A: Triplicate cultures were harvested for trypan blue exclusion cell count every 2 d; B: Doubling time of PLC-MSC was measured at every passage (B). Average doubling time PLC-MSC was 41 h. Figure 5 is representative of 3 individual experiments with ± SD, results considered significant at P < 0.05.
PLC-MSC inhibit stimulated PBMC via cell to cell contact

The effect of PLC-MSC on T-cell proliferation was evaluated by co-culturing MSC with resting or PHA stimulated T lymphocytes and measured by 3H-TdR uptake. As shown in Figure 6, PLC-MSC were unable to stimulate the resting allogenic T cell but inhibited PHA stimulated T cells proliferation in a dose dependent manner. In order to determine the mode of inhibition, PLC-MSC were also co-cultured directly and physically separated by transwell inserts. T cells proliferation was significantly inhibited in direct co-culture whereas in the transwell system the suppression of T cells proliferation was less profound and not statistically significant. Meanwhile, PLC-MSC conditioned media (supernatant) did not suppress the activated T cell proliferation.

Figure 6
Figure 6 Dose dependent inhibitory effect of placenta mesenchymal stem cells on phytohemagglutinin stimulated PBMC via cell to cell contact. A: Peripheral blood mononuclear cells (5 × 105 cells) with or without phytohemagglutinin (PHA) stimulation were co-cultured with various ratios of placenta mesenchymal stem cells (PLC-MSC) and incubated for 72 h. For the final 18 h of the culture, tritium thymidine (3H-TdR) was pulsed into the wells. PLC-MSC failed to stimulate proliferation of resting T cells but PLC-MSC inhibited activated T cells proliferation in a dose dependent mechanism; B: PBMC (2 × 106) stimulated with PHA were also co-cultured with 2 × 105 PLC-MSC (direct and indirect contact) and MSC conditioned media in a 12 well plate. T cells were harvested after 48 h of incubation, plated in 96-well plates and proliferation was measured by 3H-TdR on day 3. This result represents the average percentage of T cell proliferation ± SD of 3 repeated experiments. aP < 0.05 vs positive control (T + PHA).

In this study, we have successfully generated MSC from human placental tissue by using a combination of enzymatic digestion and mechanical dissociation[24]. The method yielded a high number of nucleated cells upon expansion. The MSC population was enriched by plastic adherence as the expansion capacity of MSC are dependent on initial plating densities and plastic source for adhesion[25,26].

The initial primary culture of placenta-derived single cell suspensions gives rise to a heterogeneous population of mainly fibroblast and epithelial-like morphology (Figure 1). This phenomenon, previously reported as a heterogeneous population in primary cultures, might be due to variations in cultivation method such as culture media, growth supplements and other pre-selection criteria[27,28]. However, endothelial-like cells do not contribute to the proliferation as they failed to proliferate at P0 and were unable to sustain beyond P0 in pre-optimised MSC complete media. Others have also reported that upon trypsinisation and subsequent sub-culture, the fibroblastic cells predominate the primary culture and continued to proliferate[29,30]. The growth kinetics measured for epithelial-like cell free cultures showed that the early passages of PLC-MSC had rapid growth kinetics and with an average doubling time of PLC-MSC of 41 h (Figure 5). However, the growth kinetics of PLC-MSC at later passage (P15 onwards) was sluggish; consisting of pro-longed lag and log phases; taking longer to attain confluence and showing higher doubling time in comparison to the earlier passages (data not shown).

We also evaluated the morphological changes of PLC-MSC throughout the numerous passages. In the early passages, PLC-MSC appeared to be firmly adherent, smaller in size and had a well defined shape. However, this morphology gradually changed as the passages increased. At later passages (P15 onwards), PLC-MSC appeared slightly bigger, elongated, less defined, less proliferative and eventually underwent senescence. According to Mareddy et al[31] and others, MSC cultures undergo senescence upon expansion, as indicated by the slow growth and reduced differentiation ability of MSC even though they still express normal levels of MSC surface markers[32]. In line with this, although the immunophenotype of later passage of PLC-MSC is unchanged (data not shown), continuous growth in culture and trypsinisation may be a major cause for loss of stemness as long term cultures are much inclined to spontaneous differentiation. In view of this, we have utilized PLC-MSC from early passages in our downstream experiments. However, the changes in morphology due to prolonged culture and trypsinisation need to be confirmed using karyotype analysis to determine cellular senescence.

There is no a single marker for depicting MSC. However, as per recommendation from International Society for Cellular Therapy (ISCT), a panel of antibodies was utilised as a minimal criterium to characterise human MSC. Dominici et al[33] have defined human MSC by immunophenotyping as they co-express CD105, CD73, CD90 while lacking expression for CD45, CD34, CD14 or CD11b, CD79α or CD19 and HLA-DR. Our expanded PLC-MSC cultures met most of these criteria and were non-hematopoietic and non-immunogenic as they did not express CD45, CD80, CD86 and MHC class II (HLA-DR) antigens while they were positive for typical MSC surface antigens (CD105, CD73, CD29, CD90 and MHC class I-Figure 2). Gene expression was found to be similar to that of BM-MSC and other sources of MSC[4,5,21]. PLC-MSC express the distinct surface proteins for MSC and at molecular level they also express ESC markers; Nanog, Sox2, Rex-1 and Oct4 (Figure 3). Similar expression patterns were also reported for chorion and amnion derived MSC[34]. These ESC markers are essential transcriptional factors and are usually expressed by pluripotent cells to maintain their undifferentiated state or “stemness”[35,36]. The intrinsic stemness properties of PLC-MSC, as measured by surface staining and expression of transcription factors at the molecular level, further supports the functional properties of MSC when they directly differentiated into osteoblasts, adipocytes and chondrocytes (Figure 4). These findings suggest that MSC derived from placenta tissues can give rise to mesodermal lineages, comparable to other sources of MSC[37,38]. However, the utilization of early passage of PLC-MSC is desirable as PLC-MSC are subject to cellular ageing.

Despite the normal expression of MHC class I, PLC-MSC failed to stimulate the proliferation of resting allogenic T cells. The hypo-immunogenicity of PLC-MSC may be due to the lack of MHC class II and co-stimulatory molecule (CD80 and CD86) expression which prevents them from presenting antigens to allogenic T cells. Nevertheless, the proliferation of PHA stimulated T cells was found to be dramatically inhibited in a dose dependent manner when co-cultured with MSC at various ratios. A similar inhibitory pattern was observed in human bone marrow derived MSC[9]. Although the transwell experiments exclude the role of soluble factors in PLC-MSC mediated immunosuppression, a noticeable yet non- significant inhibition caused by the autocrine effect of PLC-MSC secreting inflammatory cytokines in the presence of activated T cells. However, this contradicts other studies where soluble factors were also found to inhibit T cells profoundly[38,39].

In conclusion, our study has indicated that, upon successful expansion, PLC-MSC exhibit similar mesenchymal cell surface markers, an MSC-like gene expression pattern and MSC-like differentiation potential similar to other sources of MSC. This study indicates that placenta tissues have the potential to serve as an alternative to bone marrow as a source of MSC for future use experimental and clinical applications.


Mesenchymal stem cells (MSC) have been widely studied for their therapeutic use in regenerative medicine and immune related disorders. Although MSC can be derived from virtually all tissues human delivery waste tissue (placenta) represents an ideal source for MSC due to its unlimited availability and freedom from ethicalconcerns. In this study, MSC from human placenta tissues were generated and characterised by immunophenotyping, early embryonic gene expression profiling and their potential for differentiation towards osteo, adipo and chondrocytes. Furthermore, placenta-derived MSC profoundly inhibited proliferation of T cells in a dose-dependent manner via cell-to-cell contact.

Research frontiers

MSC have attracted tremendous interest in repairing tissue injuries and dampening the inflammatory response in many disease models. It has been shown that MSC have an inherent ability to home to inflammatory sites, promising great potential for targeted tissue repair and wound healing. Thus, finding an alternative source of MSC that has less ethical concerns and a continuous supply may spur the use of MSC in therapeutic applications.

Innovations and breakthroughs

In previous studies, MSC were generated using conventional enzymatic digestion giving a low yield of single cells which took a long time to develop into adherent cells. However, in this article, placenta was processed by a mechanical disassociation method and followed by a typical enzymatic digestion. The number of single cells generated by this method was extremely high and a shorter period was required for colony formation. The authors have also characterised MSC of placental origin according to all relevant parameters (surface marker expression, mesodermal differentiation, early embryonic gene expression and immunosuppression).


This study suggests the feasibility of utilising placenta-derived MSC for clinical application in regenerative medicine. Furthermore, it also confirmed the presence of MSC in human placenta.


PLC-MSC: MSC that derived from human placenta; T cell proliferation: Human T lymphocytes activated with mitogen and their cell division is measured by tritiated thymidine uptake.

Peer review

In this paper the authors demonstrate the feasibility of MSC derived from human placenta tissue, as an alternative to the bone marrow derived MSC. The authors show that the cells they isolated have features typical for MSCs. These features include the expression of CD105, CD73 and CD90, the deficiency of CD45 and CD34 as well as the ability to differentiate to adipocytes and osteocytes. The authors also demonstrate that, in line with the notion that MSCs act immunosuppressively, these cells have the potential to inhibit the proliferation of PHA-stimulated T-cells. The experimental design is simple and essential, and does demonstrate the feasible use of these cells as an alternative to the bone marrow derived MSCs, thus meeting its objective. Overall, these data are convincing in that the cells the authors isolated are most likely MSCs.


Peer reviewers: Juergen Dittmer, PhD, Clinic for Gynecology, University of Halle, Ernst-Grube-Str. 40, 06120 Halle/Saale, Germany; Arianna Scuteri, PhD, Neuroscience and Biomedical Tehnologies Department, Faculty of Medicine, University of Milan-Bicocca, Via Cadore 48, 20052, Monza (MB), Italy

S- Editor Wang JL L- Editor Hughes D E- Editor Zheng XM

1.  Minguell JJ, Conget P, Erices A. Biology and clinical utilization of mesenchymal progenitor cells. Braz J Med Biol Res. 2000;33:881-887.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 57]  [Cited by in F6Publishing: 57]  [Article Influence: 2.4]  [Reference Citation Analysis (0)]
2.  Dazzi F, Ramasamy R, Glennie S, Jones SP, Roberts I. The role of mesenchymal stem cells in haemopoiesis. Blood Rev. 2006;20:161-171.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 231]  [Cited by in F6Publishing: 230]  [Article Influence: 12.1]  [Reference Citation Analysis (0)]
3.  Fukuchi Y, Nakajima H, Sugiyama D, Hirose I, Kitamura T, Tsuji K. Human placenta-derived cells have mesenchymal stem/progenitor cell potential. Stem Cells. 2004;22:649-658.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 451]  [Cited by in F6Publishing: 433]  [Article Influence: 22.8]  [Reference Citation Analysis (0)]
4.  Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol. 2000;109:235-242.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1137]  [Cited by in F6Publishing: 1054]  [Article Influence: 43.9]  [Reference Citation Analysis (0)]
5.  Ilancheran S, Moodley Y, Manuelpillai U. Human fetal membranes: a source of stem cells for tissue regeneration and repair. Placenta. 2009;30:2-10.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 189]  [Cited by in F6Publishing: 183]  [Article Influence: 11.4]  [Reference Citation Analysis (0)]
6.  Bačenková D, Rosocha J, Tóthová T, Rosocha L, Šarisský M. Isolation and basic characterization of human term amnion and chorion mesenchymal stromal cells. Cytotherapy. 2011;13:1047-1056.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 48]  [Cited by in F6Publishing: 45]  [Article Influence: 3.8]  [Reference Citation Analysis (0)]
7.  Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, Ringdén O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439-1441.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2044]  [Cited by in F6Publishing: 1970]  [Article Influence: 98.5]  [Reference Citation Analysis (0)]
8.  Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838-3843.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2455]  [Cited by in F6Publishing: 2304]  [Article Influence: 104.7]  [Reference Citation Analysis (0)]
9.  Ramasamy R, Tong CK, Seow HF, Vidyadaran S, Dazzi F. The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. Cell Immunol. 2008;251:131-136.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 132]  [Cited by in F6Publishing: 135]  [Article Influence: 8.4]  [Reference Citation Analysis (0)]
10.  Maqbool M, Vidyadaran S, George E, Ramasamy R. Human mesenchymal stem cells protect neutrophils from serum-deprived cell death. Cell Biol Int. 2011;35:1247-1251.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 31]  [Cited by in F6Publishing: 33]  [Article Influence: 2.8]  [Reference Citation Analysis (0)]
11.  Ramasamy R, Fazekasova H, Lam EW, Soeiro I, Lombardi G, Dazzi F. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation. 2007;83:71-76.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 338]  [Cited by in F6Publishing: 324]  [Article Influence: 19.1]  [Reference Citation Analysis (0)]
12.  Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, Galun E, Rachmilewitz J. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood. 2005;105:2214-2219.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 771]  [Cited by in F6Publishing: 810]  [Article Influence: 40.5]  [Reference Citation Analysis (0)]
13.  Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;30:42-48.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1730]  [Cited by in F6Publishing: 1613]  [Article Influence: 73.3]  [Reference Citation Analysis (0)]
14.  Ramasamy R, Lam EW, Soeiro I, Tisato V, Bonnet D, Dazzi F. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia. 2007;21:304-310.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 287]  [Cited by in F6Publishing: 299]  [Article Influence: 16.6]  [Reference Citation Analysis (0)]
15.  Sarmadi VH, Tong CK, Vidyadaran S, Abdullah M, Seow HF, Ramasamy R. Mesenchymal stem cells inhibit proliferation of lymphoid origin haematopoietic tumour cells by inducing cell cycle arrest. Med J Malaysia. 2010;65:209-214.  [PubMed]  [DOI]  [Cited in This Article: ]
16.  Murphy JM, Dixon K, Beck S, Fabian D, Feldman A, Barry F. Reduced chondrogenic and adipogenic activity of mesenchymal stem cells from patients with advanced osteoarthritis. Arthritis Rheum. 2002;46:704-713.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 379]  [Cited by in F6Publishing: 354]  [Article Influence: 16.1]  [Reference Citation Analysis (0)]
17.  Imitola J, Raddassi K, Park KI, Mueller FJ, Nieto M, Teng YD, Frenkel D, Li J, Sidman RL, Walsh CA. Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc Natl Acad Sci USA. 2004;101:18117-18122.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 840]  [Cited by in F6Publishing: 838]  [Article Influence: 41.9]  [Reference Citation Analysis (0)]
18.  Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002;105:93-98.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1647]  [Cited by in F6Publishing: 1524]  [Article Influence: 69.3]  [Reference Citation Analysis (0)]
19.  Deb A, Wang S, Skelding KA, Miller D, Simper D, Caplice NM. Bone marrow-derived cardiomyocytes are present in adult human heart: A study of gender-mismatched bone marrow transplantation patients. Circulation. 2003;107:1247-1249.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 278]  [Cited by in F6Publishing: 292]  [Article Influence: 13.9]  [Reference Citation Analysis (0)]
20.  Mezey E, Key S, Vogelsang G, Szalayova I, Lange GD, Crain B. Transplanted bone marrow generates new neurons in human brains. Proc Natl Acad Sci USA. 2003;100:1364-1369.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 426]  [Cited by in F6Publishing: 397]  [Article Influence: 18.9]  [Reference Citation Analysis (0)]
21.  Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-147.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 15372]  [Cited by in F6Publishing: 14761]  [Article Influence: 590.4]  [Reference Citation Analysis (0)]
22.  Rao MS, Mattson MP. Stem cells and aging: expanding the possibilities. Mech Ageing Dev. 2001;122:713-734.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 242]  [Cited by in F6Publishing: 260]  [Article Influence: 11.3]  [Reference Citation Analysis (0)]
23.  Ayuzawa R, Doi C, Rachakatla RS, Pyle MM, Maurya DK, Troyer D, Tamura M. Naïve human umbilical cord matrix derived stem cells significantly attenuate growth of human breast cancer cells in vitro and in vivo. Cancer Lett. 2009;280:31-37.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 90]  [Cited by in F6Publishing: 76]  [Article Influence: 5.1]  [Reference Citation Analysis (0)]
24.  Tong CK, Vellasamy S, Tan BC, Abdullah M, Vidyadaran S, Seow HF, Ramasamy R. Generation of mesenchymal stem cell from human umbilical cord tissue using a combination enzymatic and mechanical disassociation method. Cell Biol Int. 2011;35:221-226.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 66]  [Cited by in F6Publishing: 69]  [Article Influence: 5.3]  [Reference Citation Analysis (0)]
25.  Sotiropoulou PA, Perez SA, Salagianni M, Baxevanis CN, Papamichail M. Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells. 2006;24:462-471.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 453]  [Cited by in F6Publishing: 434]  [Article Influence: 22.8]  [Reference Citation Analysis (0)]
26.  Schallmoser K, Bartmann C, Rohde E, Reinisch A, Kashofer K, Stadelmeyer E, Drexler C, Lanzer G, Linkesch W, Strunk D. Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion. 2007;47:1436-1446.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 380]  [Cited by in F6Publishing: 372]  [Article Influence: 21.9]  [Reference Citation Analysis (0)]
27.  Chase LG, Lakshmipathy U, Solchaga LA, Rao MS, Vemuri MC. A novel serum-free medium for the expansion of human mesenchymal stem cells. Stem Cell Res Ther. 2010;1:8.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 170]  [Cited by in F6Publishing: 162]  [Article Influence: 11.6]  [Reference Citation Analysis (0)]
28.  Carrancio S, López-Holgado N, Sánchez-Guijo FM, Villarón E, Barbado V, Tabera S, Díez-Campelo M, Blanco J, San Miguel JF, Del Cañizo MC. Optimization of mesenchymal stem cell expansion procedures by cell separation and culture conditions modification. Exp Hematol. 2008;36:1014-1021.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 115]  [Cited by in F6Publishing: 121]  [Article Influence: 7.6]  [Reference Citation Analysis (0)]
29.  Yen BL, Huang HI, Chien CC, Jui HY, Ko BS, Yao M, Shun CT, Yen ML, Lee MC, Chen YC. Isolation of multipotent cells from human term placenta. Stem Cells. 2005;23:3-9.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 322]  [Cited by in F6Publishing: 343]  [Article Influence: 18.1]  [Reference Citation Analysis (0)]
30.  Miao Z, Jin J, Chen L, Zhu J, Huang W, Zhao J, Qian H, Zhang X. Isolation of mesenchymal stem cells from human placenta: comparison with human bone marrow mesenchymal stem cells. Cell Biol Int. 2006;30:681-687.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 1]  [Reference Citation Analysis (0)]
31.  Mareddy S, Crawford R, Brooke G, Xiao Y. Clonal isolation and characterization of bone marrow stromal cells from patients with osteoarthritis. Tissue Eng. 2007;13:819-829.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 1]  [Reference Citation Analysis (0)]
32.  Halleux C, Sottile V, Gasser JA, Seuwen K. Multi-lineage potential of human mesenchymal stem cells following clonal expansion. J Musculoskelet Neuronal Interact. 2001;2:71-76.  [PubMed]  [DOI]  [Cited in This Article: ]
33.  Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-317.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 11055]  [Cited by in F6Publishing: 11766]  [Article Influence: 692.1]  [Reference Citation Analysis (1)]
34.  Rus Ciucă D, Soriţău O, Suşman S, Pop VI, Mihu CM. Isolation and characterization of chorionic mesenchyal stem cells from the placenta. Rom J Morphol Embryol. 2011;52:803-808.  [PubMed]  [DOI]  [Cited in This Article: ]
35.  Shi W, Wang H, Pan G, Geng Y, Guo Y, Pei D. Regulation of the pluripotency marker Rex-1 by Nanog and Sox2. J Biol Chem. 2006;281:23319-23325.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 136]  [Cited by in F6Publishing: 138]  [Article Influence: 7.7]  [Reference Citation Analysis (0)]
36.  Hyslop L, Stojkovic M, Armstrong L, Walter T, Stojkovic P, Przyborski S, Herbert M, Murdoch A, Strachan T, Lako M. Downregulation of NANOG induces differentiation of human embryonic stem cells to extraembryonic lineages. Stem Cells. 2005;23:1035-1043.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 293]  [Cited by in F6Publishing: 303]  [Article Influence: 15.9]  [Reference Citation Analysis (0)]
37.  Brooke G, Rossetti T, Pelekanos R, Ilic N, Murray P, Hancock S, Antonenas V, Huang G, Gottlieb D, Bradstock K. Manufacturing of human placenta-derived mesenchymal stem cells for clinical trials. Br J Haematol. 2009;144:571-579.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 117]  [Cited by in F6Publishing: 124]  [Article Influence: 8.3]  [Reference Citation Analysis (0)]
38.  Jones BJ, Brooke G, Atkinson K, McTaggart SJ. Immunosuppression by placental indoleamine 2,3-dioxygenase: a role for mesenchymal stem cells. Placenta. 2007;28:1174-1181.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 99]  [Cited by in F6Publishing: 105]  [Article Influence: 6.2]  [Reference Citation Analysis (0)]
39.  Yang SH, Park MJ, Yoon IH, Kim SY, Hong SH, Shin JY, Nam HY, Kim YH, Kim B, Park CG. Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. Exp Mol Med. 2009;41:315-324.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 170]  [Cited by in F6Publishing: 166]  [Article Influence: 11.1]  [Reference Citation Analysis (0)]